Lower dose abiraterone without hormone shots for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a lower dose of abiraterone (a pill that lowers testosterone) without the usual hormone-blocking shots for men with prostate cancer that needs hormone therapy. It is for patients at high risk or with early spread who have not had hormone therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have prostate cancer that was confirmed by a biopsy.
- You are being treated at Hospital Durand in Argentina or Instituto Oncológico del Oriente Boliviano in Bolivia.
- Your doctor recommends hormonal therapy for high-risk prostate cancer or for cancer that has spread but is still hormone-sensitive.
- You have not had hormone therapy (like Lupron or Zoladex) before.
- You are in good general health, with normal kidney and liver function, normal potassium levels, and controlled blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.